BioSpace News Archive

Fluidigm Corporation announced that it intends to offer, subject to market conditions and other factors, $45 million of aggregate principal amount of convertible senior notes due 2024 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score [CPS] ≥1)

Aravive, Inc. (Nasdaq: ARAV) today announced new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients.

Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced that the American College of Rheumatology (ACR) has included the Vectra® test in its list of recommended disease activity measures for patients with rheumatoid arthritis (RA)

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced publication of results from two Phase 1 pharmacokinetic (PK) studies of IV oliceridine, one in patients with end-stage renal disease and one in patients with hepatic impairment, in Clinical Pharmacology in Drug Development.

Emerald Health Therapeutics, Inc. responded to inaccurate allegations made by Village Farms International, Inc. in connection with their 50/50 joint venture, Pure Sunfarms Corp., and updated the market on certain related matters.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, today announced its collaboration with Idaho Urologic Institute, PA (IUI) in the Cchek™ early cancer detection study.

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences

VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the results of a clinical study (NCT02553824) demonstrating that patients with binge-eating disorder (BED) or bulimia nervosa (BN) receiving Qsymia (phentermine and topiramate extended-release (ER)) capsules CIV had a significant reduction in binge day frequency compared with placebo over four weeks

Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed funds will acquire Cynosure, LLC, a leader in medical aesthetics systems and technologies, from Hologic, Inc. (NASDAQ:HOLX).